In addition, conceivably, the anticipated introduction of universal tumor tissue screening for BRAF-mutations and MMR protein expression for treatment stratification purposes (Cohen et al. 2017) will alter current patient referral patterns, in particular for LS. This evidence concerns the gene BRAF and neoplasm.